Loading...
XPAR
NANO
Market cap1.88bUSD
Jul 10, Last price  
35.56EUR
1D
4.28%
1Q
39.01%
Jan 2017
130.31%
IPO
429.17%
Name

Nanobiotix SA

Chart & Performance

D1W1MN
XPAR:NANO chart
P/E
—
P/S
58.05
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.42%
Rev. gr., 5y
66.38%
Revenues
30m
P
1,360,314970,6081,595,4662,770,7954,015,2285,421,6133,722,0003,479,0002,541,0002,325,0002,647,0004,776,00036,208,000-7,190,00029,643,000
Net income
-24m
L-64.83%
-5,246,579-5,330,896-8,144,920-9,556,525-17,003,084-21,880,511-26,143,000-30,345,000-50,915,000-33,590,000-47,003,000-57,041,000-39,700,000-68,132,000-23,961,000
CFO
-33m
L+70.95%
-4,873,240-3,756,113-6,830,566-8,564,825-16,820,489-18,283,766-20,949,000-25,985,000-41,169,000-27,538,000-29,872,000-37,103,000-12,476,000-19,551,000-33,422,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Nanobiotix S.A. is a clinical-stage biotechnology firm dedicated to advancing innovative therapeutic candidates for oncology. Its flagship experimental treatment, NBTXR3, is a sterile, water-based suspension composed of crystalline hafnium oxide nanoparticles. This compound is under investigation for its potential in addressing a wide array of cancers, including soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, and rectal cancers, along with non-small cell lung cancer. To facilitate the development and market entry of NBTXR3, Nanobiotix S.A. has formed a strategic partnership with LianBio, targeting Greater China, South Korea, Singapore, and Thailand. The company was founded in 2003 and its main operations are based in Paris, France.
URL
https://www.nanobiotix.com
IPO date
Oct 29, 2012
Employees
102
Domiciled in
FR
Incorporated in
FR

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT